Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EMC NYSEAMERICAN:PFNX TSE:RVX NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$31.36+0.6%$0.00$22.99▼$29.13N/AN/A13.90 million shs10,623 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ARVXResverlogixC$0.10+5.3%C$0.11C$0.04▼C$0.30C$28.64M1.154049109,974 shs30,000 shsTLXTelix Pharmaceuticals$9.16-2.3%$12.00$8.93▼$30.36$3.10BN/A66,707 shs247,240 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC+0.92%+2.67%+5.43%+10.59%+17.63%PFNXPfenex0.00%0.00%0.00%0.00%0.00%RVXResverlogix0.00%+2.70%-13.64%+137.50%+46.15%TLXTelix Pharmaceuticals-0.42%-3.20%-21.18%-44.69%+937,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$31.36+0.6%$0.00$22.99▼$29.13N/AN/A13.90 million shs10,623 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ARVXResverlogixC$0.10+5.3%C$0.11C$0.04▼C$0.30C$28.64M1.154049109,974 shs30,000 shsTLXTelix Pharmaceuticals$9.16-2.3%$12.00$8.93▼$30.36$3.10BN/A66,707 shs247,240 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC+0.92%+2.67%+5.43%+10.59%+17.63%PFNXPfenex0.00%0.00%0.00%0.00%0.00%RVXResverlogix0.00%+2.70%-13.64%+137.50%+46.15%TLXTelix Pharmaceuticals-0.42%-3.20%-21.18%-44.69%+937,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMC 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/ARVXResverlogix 0.00N/AN/AN/ATLXTelix Pharmaceuticals 2.83Moderate Buy$21.50134.72% UpsideCurrent Analyst Ratings BreakdownLatest PFNX, EMC, TLX, and RVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025TLXTelix PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.009/10/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$23.00 ➝ $20.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.007/9/2025TLXTelix PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ATLXTelix Pharmaceuticals$516.72M6.00$0.11 per share82.49$1.12 per share8.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0515.30∞N/AN/AN/AN/AN/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ARVXResverlogix-C$2.81M-C$0.04N/A∞N/AN/A6.06%-34.90%N/ATLXTelix Pharmaceuticals$32.93MN/A0.0019.08N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.47%N/A22.44%N/APFNXPfenexN/AN/AN/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/APFNXPfenexN/AN/AN/ARVXResverlogix-10.950.130.04TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%PFNXPfenexN/ARVXResverlogix0.01%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEMCEMC0.40%PFNXPfenexN/ARVXResverlogix42.66%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionableRVXResverlogix19286.44 millionN/ANot OptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/APFNX, EMC, TLX, and RVX HeadlinesRecent News About These CompaniesTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You ...September 16 at 11:22 PM | bakersfield.comBTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 16 at 6:18 PM | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 15 at 6:13 PM | prnewswire.comTELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the FirmSeptember 15 at 5:39 PM | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down After Analyst DowngradeSeptember 13, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down Following Analyst DowngradeSeptember 13, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Given New $20.00 Price Target at HC WainwrightSeptember 12, 2025 | marketbeat.comTELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the FirmSeptember 11, 2025 | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 11, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens BermanSeptember 11, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?September 11, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Price Target Cut to $20.00 by Analysts at HC WainwrightSeptember 11, 2025 | americanbankingnews.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 10, 2025 | prnewswire.comTelix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer DiagnosisSeptember 9, 2025 | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 7, 2025 | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 5, 2025 | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low - What's Next?September 5, 2025 | marketbeat.comTelix Pharmaceuticals (ASX:TLX) Hits New Low Amid FDA ScrutinySeptember 5, 2025 | thebull.com.auTTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - What's Next?September 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXSeptember 3, 2025 | prnewswire.comTelix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response LetterSeptember 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePFNX, EMC, TLX, and RVX Company DescriptionsEMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Resverlogix TSE:RVXC$0.10 +0.01 (+5.26%) As of 03:39 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.Telix Pharmaceuticals NASDAQ:TLX$9.16 -0.22 (-2.35%) Closing price 04:00 PM EasternExtended Trading$9.25 +0.09 (+0.99%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
